Find Your Fit: 4 New Additions to the Belkin SoundForm Audio Collection Announced at IFA 2024
5.9.2024 11:00:00 EEST | Business Wire | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced 4 new products across its SoundForm audio category, underscoring Belkin innovation, quality and its commitment to building products more responsibly. Belkin International can be found on the IFA show floor, Exhibit Hall 3.2, stand #210.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905446437/en/
Belkin announces new SoundForm portfolio at IFA 2024 (Photo: Business Wire)
Designed in its in-house labs at Belkin Global Headquarters in California, every SoundForm product undergoes 150 meticulous quality tests, ensuring perfection before it reaches consumer’s ears. Design, sound quality, comfort, voice-calling performance, enhanced features and value are all considered with each new addition to the SoundForm portfolio.
Belkin Signature Sound is integrated throughout the SoundForm range. Developed by Belkin sound engineers, it allows the wearer to listen to music exactly the way the artist intended. Deep bass is balanced, vocals are crystal-clear, and treble is crisp. To do this, Belkin sound engineers test headphone and earphone frequency response and distortion, passive noise isolation, Environmental Noise Cancellation (ENC), Active Noise Cancellation (ANC) performance, and Sound Pressure Level (SPL) to ensure proper 98db output for ‘adult’ products and 85db ‘safe sound’ for ‘kids’ products—and more. All new SoundForm products feature ENC for voice isolating clear call quality as standard.
Consumers will find a product in the SoundForm collection to suit their needs–all without breaking the bank.
SoundForm Rhythm
The SoundForm Rhythm earbuds pack a punch while taking up minimal space. They were designed for consumers looking for a casual pair of earbuds for entertainment, work/study purposes, or daily use.
Features:
- Design: True wireless, stem-shaped
- Sound: 6mm drivers
- Battery life: 8 hours with an additional 20 hours of battery life in charging case; 10 minutes of charge gets 90 minutes of playtime
- Connection: Bluetooth 5.3 and Multipoint
- Included in package: USB-C fast charging compatible case
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $34.99 / £24.99 / €29.99
Availability: SoundForm Rhythm is available now on belkin.com and select retailers worldwide
SoundForm ClearFit
Get a (good) grip with the SoundForm ClearFit. When it’s time to move, ClearFit is a go-to. Perfect for sports, outdoor activities and workouts, these earbuds stay comfortably secured around the outer ear for great sound while allowing the user to stay aware of their surroundings.
Features:
- Design: Open-ear, secure, comfortable and IPx5 sweat resistant
- Sound: 14.2mm drivers
- Battery life: 8 hours with an additional 18 hours of battery life in charging case; 10 minutes of charge gets 90 minutes of playtime
- Connection: Bluetooth 5.3 and Multipoint
- Included in package: USB-C fast charging compatible case
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $59.99 / £39.99 / €49.99
Availability: SoundForm ClearFit is available now on belkin.com/de and belkin.com/uk and select retailers worldwide
SoundForm Isolate
The SoundForm Isolate is the first over-ear headphone with ANC by Belkin. Made for the modern and stylish individual, Isolate provides quality ANC at a reasonable price point. In addition to ANC, Isolate also has a built-in “Relaxation” track that plays on a loop for moments where you need to further tune out external noise. They come with a long battery life of 60 hours, 3 settings (Standard Listening, Active Noise Cancellation, Hear Thru Mode) and Bluetooth multipoint – all in a sleek and portable design.
Features:
- Design: Over-ear, foldable, extendable and comfortable with 5 mics and intuitive touch controls to easily manage sound with a tap
- Sound: 40mm drivers
- Battery life: 60 hours of battery life (40 hours with ANC on)
- Connection: Bluetooth 5.4 and Multipoint
- Included in package: USB-C charging and audio cable; 3.5mm audio cable for users that prefer wired connection
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $59.99 / £49.99 / €59.99
Availability: SoundForm Isolate will be available from Autumn 2024
SoundForm Surround
The SoundForm Surround over-ear headphones are perfect for when you need to chat on the go. ENC ensures clear calls with background noise kept to a whisper. Its foldable, extendable, and comfortable over-ear design and intuitive touch controls make SoundForm Surround an everyday accessory.
Features:
- Design: Over-ear, foldable, extendable and comfortable with intuitive touch controls to easily manage sound with a tap
- Sound: 40mm drivers
- Battery life: 60 hours
- Connection: Bluetooth 5.4 and Multipoint
- Included in package: USB-C charging and audio cable; 3.5mm audio cable for users that prefer wired connection
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $39.99 / £29.99 / €39.99
Availability: SoundForm Surround will be available from Autumn 2024
All new products are made with post-consumer recycled (PCR) plastics in line with the company’s commitment to find more responsible ways to build products. They will be on display at IFA 2024.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905446437/en/
Contacts
For Media Inquiries:
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom